Samsung Biologics aims to raise 2.25t won in IPO
Seoul
SAMSUNG Biologics Co is seeking to raise as much as 2.25 trillion won (S$2.77 billion) from a South Korean initial public offering, taking an important step towards its goal of becoming the world's largest contract manufacturer of biological medicines.
The drug-making arm of the South Korean conglomerate will offer about 16.5 million shares at 113,000- 136,000 won apiece, according to a filing on Tuesday. Samsung Biologics will gauge demand for the share sale from Oct 26 to 27 with a final price to be announced on Oct 28.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Chinese tariffs could leave cognac makers with too much brandy
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales